Table 4.
Local delivery strategies used for biologic delivery to restore immune homeostasis from inflammation.
| Biologics | Delivery Strategy | Disease Model | Ref(s) |
|---|---|---|---|
| Antibodies | |||
| Anti-IL-6R mAb | GelMA hydrogel | Skin transplantation | [118] |
| Anti-TNFa mAb | PLGA MPs | In vitro neutralization | [179] |
| Self-assembled nanofiber hydrogel | In vitro neutralization | [180] | |
| CTLA4-Ig | Acellular dermal matrices | Islet transplantation | [39] |
| pNIPAAM-chitosan-hyaluronic hydrogel | Islet transplantation | [76] | |
| TNF-Ig | MPEG-PCL-MPEG MPs | - | [46] |
| Cytokines | |||
| GM-CSF | Puramatrix™ hydrogel | Inflammatory diabetes | [186] |
| Interleukin-2 | Alginate-GelMA hydrogel | Islet transplantation | [90] |
| Interleukin-33 | PLG scaffold | Islet transplantation | [197] |
| Interleukin-1Ra | Gelatin MPs | Islet transplantation | [76] |
| Pluronic F127 hydrogel | - | [81] | |
| b-TCP MP | - | [199] | |
| FasL | Agarose hydrogel-lipid microtubes | Cell transplantation | [109] |
| PEG hydrogel MPs (microgels) | Islet transplantation | [201] | |
| TGF-β1 | Alginate scaffold | Allogenic cell transplantation | [99] |
| PLGA MPs | Vascularized composite allotransplantation | [30] | |
| PEG-PLGA MPs | Inflammatory arthritis | [190] | |
| Chemokines | |||
| CCL22 | PLGA MPs | Allogeneic cell transplantation | [210] |
| PLGA MPs | Vascularized composite allotransplantation | [44] | |
| CXCL12 | Alginate MPs | Islet transplantation | [98] |
| CCL1 | Alginate-GelMA hydrogel | Islet transplantation | [90] |